EcoDrugPlus

Ribosomal Protein L39

Ensembl ID : ENSBTAG00000049833
Gene Symbol: RPL39
15 Enzyme and pathways 4 Cross references
88 Possible Orthologues:

Ribosomal Protein L4

Ensembl ID : ENSBTAG00000005211
Gene Symbol: RPL4
15 Enzyme and pathways 4 Cross references
290 Possible Orthologues:

Ribosomal Protein L6

Ensembl ID : ENSBTAG00000031723
Gene Symbol: RPL6
15 Enzyme and pathways 4 Cross references
407 Possible Orthologues:

Ribosomal Protein L7

Ensembl ID : ENSBTAG00000020139
Gene Symbol: RPL7
15 Enzyme and pathways 4 Cross references
273 Possible Orthologues:

Ribosomal Protein L8

Ensembl ID : ENSBTAG00000026327
Gene Symbol: RPL8
15 Enzyme and pathways 4 Cross references
293 Possible Orthologues:

Ribosomal Protein L9

Ensembl ID : ENSBTAG00000014518
Gene Symbol: RPL9
15 Enzyme and pathways 4 Cross references
224 Possible Orthologues:

Ribosomal Protein S10

Ensembl ID : ENSBTAG00000015598
Gene Symbol: RPS10
19 Enzyme and pathways 5 Cross references
294 Possible Orthologues:

Ribosomal Protein S11

Ensembl ID : ENSBTAG00000013924
Gene Symbol: RPS11
19 Enzyme and pathways 5 Cross references
227 Possible Orthologues:

Ribosomal Protein S13

Ensembl ID : ENSBTAG00000040308
Gene Symbol: RPS13
19 Enzyme and pathways 4 Cross references
295 Possible Orthologues:

Ribosomal Protein S14

Ensembl ID : ENSBTAG00000008570
Gene Symbol: RPS14
4 Cross references
315 Possible Orthologues:

Ribosomal Protein S15

Ensembl ID : ENSBTAG00000019718
Gene Symbol: RPS15
19 Enzyme and pathways 5 Cross references
242 Possible Orthologues:

Ribosomal Protein S2

Ensembl ID : ENSBTAG00000009535
Gene Symbol: RPS2
5 Cross references
314 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).